BioSpace News Archive

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23M.

The company is lowering its full fiscal year 2020 revenue and adjusted diluted earnings per share guidance to reflect the impact of the remediation effort and anticipated loss of sales of the Alaris infusion system.

Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced the appointment of Mr. Siu Chuen Cheng as a new independent non-executive director to the Board of Directors of the Company (the “Board”).

Cardinal Health (NYSE: CAH) today reported financial results for the second quarter of fiscal 2020 ended December 31, 2019. Second quarter revenue was $39.7 billion, an increase of 5% from the second quarter of last year.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees options to purchase an aggregate of 140,000 shares of BioCryst common stock on January 31, 2020 as inducements material to each employee entering into employment with BioCryst.

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today highlighted several new research studies on the increasing prevalence of type one diabetes (T1D) and the importance of screening for this life-impacting and life-threatening autoimmune disease.

Feb. 6, 2020 12:00 UTC CAMBRIDGE, Mass.--( BUSINESS WIRE )-- AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 91,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with NASDAQ Listing R

Feb. 6, 2020 12:00 UTC SAINT PAUL, Minn.--( BUSINESS WIRE )-- Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria CV Pulmonary Hypertension System (Aria CV PH System). The Breakthrough Devices Program (BDP) is intended to expedite the FDA review and approval of designated devices that may provide more effective tre

WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday, February 20, 2020. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2019. The conference call will be accessible b

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, one of the largest hyperbaric medical centers in the world, today announced that its Chief Medical Research Officer, Amir Hadanny, MD, will participate on a panel discussion at this year’s Synapse Summit, entitled, Aging Gracefully: Innovations Improving Life for Millions of Seniors.